Concept Architecture
Concept
Theoretically, N-of-1 Trial is a multiple crossover experimental study in which a single participant undergoes repeated periods of alternative treatments according to a randomised treatment sequence. The concept is founded on repeated measures methodology, crossover trial design and individualised clinical decision-making. It exists to determine the comparative effectiveness of interventions for an individual patient by minimising between-person variability and providing direct evidence of treatment response at the individual level.
Mathematically, N-of-1 Trials are represented using repeated within-participant comparisons in which treatment effects are estimated from multiple crossover periods. Statistical analysis commonly involves paired comparisons, linear mixed-effects models, Bayesian hierarchical models or time-series methods that account for repeated observations, treatment periods and serial correlation. Randomisation ensures unbiased allocation of treatment periods, while repeated measurements improve the precision of individual treatment effect estimates.
In practice, a participant is randomly assigned to a sequence of treatment periods, such as ABBAAB or BAABBA, with washout intervals incorporated where necessary to minimise carryover effects. Clinical outcomes are measured during each treatment period, and treatment effects are estimated by comparing repeated observations within the same individual. N-of-1 Trials are particularly valuable for chronic stable conditions, rare diseases and personalised medicine, and may contribute evidence supporting individual treatment decisions and health economic evaluations where patient-specific effectiveness is relevant.
Purpose
Used to determine the comparative effectiveness of alternative interventions for an individual patient through repeated randomised treatment comparisons, supporting personalised clinical and health economic decision-making.
Mathematical Formulae
Primary Formula
Within-participant treatment effect:
? = (1/k) ? ?(Y?? ? Y??)
where:
- ? = estimated individual treatment effect
- Y?? = outcome during Treatment A in period i
- Y?? = outcome during Treatment B in period i
- k = number of paired treatment comparisons
Supporting Formulae
Mean treatment difference:
d? = (1/n) ? ?d?
Paired t-statistic:
t = d? / (s_d / �n)
where:
- d? = paired treatment difference
- s_d = standard deviation of paired differences
- n = number of paired treatment periods
Related Mathematical Methods
- Crossover Trial
- Paired t-Test
- Bayesian Hierarchical Modelling
- Linear Mixed-Effects Models
- Time-Series Analysis
- Randomisation
- Repeated Measures Analysis
Example
A patient with chronic neuropathic pain participates in an N-of-1 Trial comparing a new analgesic with standard therapy over six treatment periods following the sequence ABBAAB. Pain scores are recorded weekly using a 10-point numerical rating scale. The average pain score is 3.4 during Treatment A and 5.1 during Treatment B.
? = 3.4 ? 5.1 = ?1.7
The repeated within-patient comparisons consistently favour Treatment A, supporting continued treatment for this individual. The findings may also contribute to patient-level evidence used in personalised health economic decision-making.
Excel Implementation
| Function | Example Formula | Health Economics Application |
|---|---|---|
| AVERAGE | =AVERAGE(B2:B7) | Calculate the mean outcome during one treatment period. |
| AVERAGE | =AVERAGE(C2:C7) | Calculate the mean outcome during the comparator treatment period. |
| T.TEST | =T.TEST(B2:B7,C2:C7,2,1) | Perform a paired comparison between repeated treatment periods. |
| STDEV.S | =STDEV.S(D2:D7) | Estimate the variability of paired treatment differences. |
| IF | =IF(AVERAGE(B2:B7)<AVERAGE(C2:C7),"Treatment A Better","Treatment B Better") | Identify the preferred treatment for the individual participant. |
VBA (Optional)
VBA can automate randomised treatment sequences, summarise repeated treatment periods and generate patient-specific effectiveness reports for N-of-1 Trials.
Sources
- Guyatt GH, Sackett DL, Taylor DW, et al. Determining Optimal Therapy?Randomized Trials in Individual Patients. New England Journal of Medicine.
- Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The N-of-1 Clinical Trial: The Ultimate Strategy for Individualizing Medicine? Personalized Medicine.
- Senn S. Cross-Over Trials in Clinical Research.
- Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J. Combining Single Patient (N-of-1) Trials to Estimate Population Treatment Effects.
- NICE. Health Technology Evaluation Manual.
- Drummond MF, et al. Methods for the Economic Evaluation of Health Care Programmes.
Related Concepts (2)
Library
Publications
1
Economic Evaluation in Clinical Trials — Glick, Doshi, Sonnad & Polsky, 2nd Edition ed., 2015 (Oxford University Press)
Practical guidance on conducting cost-effectiveness analyses alongside controlled trials, covering trial design, measurement of costs and quality-adjusted life years, handling censored and missing data, and reporting stochastic uncertainty. Volume 4 in the Handbooks in Health Economic Evaluation series.
BookView source →
Frequently Asked Questions (6)
What is an n-of-1 trial?
A trial conducted within a single participant, repeatedly alternating experimental treatment and control in random, blinded sequence to determine its individual effect.
Source: Guyatt et al. 1986
Why does an n-of-1 trial suit an individual treatment decision?
An n-of-1 trial runs the comparison within a single patient, alternating the treatment and a control in random, blinded order over several periods and comparing the patient's own responses. Because the aim is to find what works for that particular person rather than for patients on average, it directly answers an individual treatment decision, especially for a chronic condition with a quick, reversible response. It brings the rigour of randomisation and blinding to the care of one patient. It personalises the evidence. Guyatt and colleagues (1986) describe this design.
Source: Guyatt et al. 1986
How does an n-of-1 trial work?
An n-of-1 trial works by having a single participant undergo multiple pairs or periods of treatment and control in a random sequence, usually with blinding and washout between periods, while their outcomes are measured each time. Comparing the participant's responses during treatment and control periods indicates whether the treatment benefits them. Repeating the periods provides multiple within-person comparisons, strengthening the conclusion for that individual. The design relies on a stable, chronic condition and a treatment with a reasonably quick, reversible effect, so each period reflects the current treatment.
Source: Guyatt et al. 1986
When is an n-of-1 trial appropriate?
An n-of-1 trial is appropriate for chronic, stable conditions where symptoms persist and can be measured repeatedly, and for treatments with a reasonably rapid onset and reversible effect that does not carry over, so that alternating periods give valid comparisons. It suits situations where the benefit of a treatment for a particular patient is uncertain and worth establishing individually, such as when the population evidence is unclear or the patient's response is idiosyncratic. It is not suitable for acute or progressive conditions or treatments with lasting effects.
Source: Friedman, Furberg & DeMets 2015
What are the benefits of an n-of-1 trial?
The benefits of an n-of-1 trial are that it provides rigorous, individualised evidence about whether a treatment works for a specific patient, applying randomisation, blinding, and repeated comparison to reduce bias and the influence of chance and placebo effects, which uncontrolled trials of therapy in a single patient lack. This can guide personalised treatment decisions more reliably than trial-and-error. By tailoring the rigour of a randomised trial to the individual, n-of-1 trials support better-informed choices for patients whose response to treatment is uncertain.
Source: Guyatt et al. 1986
What are the limitations of n-of-1 trials?
The limitations of n-of-1 trials are that they apply only to conditions and treatments suited to repeated, reversible periods, excluding acute, progressive, or slowly acting cases; they require time and multiple periods, which can be burdensome; and their results apply to the individual rather than generalising to others. Combining multiple n-of-1 trials can inform group-level conclusions, but a single one is individual-specific. Carryover and period effects must be managed. These limitations mean n-of-1 trials are used selectively, for suitable conditions and treatments where individualised evidence is valuable.
Source: Guyatt et al. 1986
Trust Record
Verified by Dr Darrin Baines
British health economist
Professional identity: darrinbaines.org
Verification date: 14 Nov 2025
Content version: 1.0.0
Canonical Identity
- Persistent URI
- https://healtheconomics.wiki/concept/n-of-1-trial
- Term code
- HE-ES-CTM-055
Stable URI · Machine-readable · Resolvable · CC BY 4.0